ROCKVILLE, Md.--(BUSINESS WIRE)--GlycoMimetics, Inc. (NASDAQ: GLYC) today announced that initial efficacy data from a Phase 1/2 clinical trial on the effects of drug candidate GMI-1271 combined with chemotherapy on patients with acute myeloid leukemia (AML) were accepted as a poster to be presented at the European Hematology Association’s 21st Congress, taking place June 9-12 in Copenhagen, Denmark.
The poster (P191), entitled “Results of a Phase 1 study of GMI-1271, a novel E-selectin antagonist in combination with induction chemotherapy in relapse/refractory AML: a novel, well-tolerated regimen with a high remission rate,” is scheduled for 5:15 p.m. CET on Friday, June 10.
The abstract is available here
GMI-1271 is designed to block E-selectin (an adhesion molecule on cells in the bone marrow) from binding with acute myeloid leukemia (AML) cells in ways that help the cancer cells evade the effects of chemotherapy treatment. Preclinical research points to the drug’s potential role in moving cancerous cells out of the protective environment of the bone marrow where they hide and escape the effects of chemotherapy. By blocking E-selectin, GMI-1271 also may protect normal blood-producing cells, and reduce the toxic side effects of chemotherapy such as low white blood cell counts that make some patients more prone to infections. GMI-1271 may also reduce mucositis (inflammation or lesions in the intestinal tract and mouth), which can be a side effect of chemotherapy. GlycoMimetics has announced encouraging initial top line data from the first two cohorts in its ongoing Phase 1/2 clinical study.
About GlycoMimetics, Inc.
GlycoMimetics is a clinical-stage biotechnology company focused on sickle cell disease and cancer. GlycoMimetics' first drug candidate, rivipansel, a pan-selectin antagonist, is being developed for the treatment of vaso-occlusive crisis in sickle cell disease and is being evaluated in a Phase 3 clinical trial being conducted by its strategic collaborator, Pfizer. GlycoMimetics' wholly-owned drug candidate, GMI-1271, an E-selectin antagonist, is being evaluated in an ongoing Phase 1/ 2 clinical trial as a potential treatment for AML and other blood disorders. GlycoMimetics expects to file an IND with the FDA for a third drug candidate, GMI-1359, a combined CXCR4 and E-selectin antagonist, in the third quarter of 2016. GlycoMimetics is located in Rockville, MD in the BioHealth Capital Region. Learn more at www.glycomimetics.com.